关于 "Cytoskeleton & Motor Proteins" 的结果111+ 个结果
- (Lys¹⁵)-Amyloid β-Protein (15-21)CAS: 190775-14-5
KKLVFFA contains the KLVFF sequence, which is the minimum sequence binding the full-length amyloid β-protein. It showed improved water solubility compared with KLVFF (H-3682). It can be used as a labeled probe for screening defined sequences in the full-length amyloid β-protein.
- (Lys²²)-Amyloid β-Protein (1-40)CAS: 302905-01-7
The Italian mutation of β-amyloid 1-40 (E22K) aggregates more rapidly than the wild-type sequence 1-40. It showed increased neurotoxicity, which (according to a solid-phase NMR-study of Masuda et al.) may be due to the salt bridge formed between Lys²² and Asp²³ in the minor conformer. As the Arctic, Flemish, and Dutch mutants, the Italian mutant is degraded considerably more slowly than wild-type Aβ by neprilysin.
- (Lys²²)-Amyloid β-Protein (1-42)CAS: 383200-59-7
The Italian mutation (E22K) aggregates more rapidly than the wild-type sequence.
- (Nle³⁵)-Amyloid β-Protein (1-40)CAS: 1802086-31-2
The reactive thioether of Met³? is crucial for the activity of Aβ 1-40 and Aβ 1-42. Due to the replacement of Met by inert Nle, M35Nle Aβ 1-40 was no longer toxic to cultured hippocampal neurons and had little effect on the level of protein carbonyl residues. The Nle peptide showed the same propensity to aggregate, whereas sulfoxide formation hindered the required conformational transition from random coil to β-sheet.
- (Nle³⁵)-Amyloid β-Protein (1-42)CAS: 1802086-51-6
The thioether of Met³? plays a critical role in the oxidative stress induced by Aβ 1-42 and its neurotoxicity. The norleucine analog Aβ 1-42 M35Nle forms fibrils morphologically indistinguishable from the ones of the native sequence though lacking their neurotoxicity.
- (Pyr¹¹)-Amyloid β-Protein (11-40)CAS: 192377-94-9
pEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV, the N-terminally truncated isoform of the amyloid β-protein (Aβ) beginning with a pyroglutamate (Pyr) residue at position 11 was used in experiments studying the generality of fibrillogenesis-related helix formation. Comparing the fibrillogenesis kinetics of many of the most important clinically relevant amyloid β-protein alloforms it could be observed that among these peptides (Pyr¹¹)-amyloid β-protein (11-40) exhibited the greatest retardation of fibrillization rate.
- (Pyr³)-Amyloid β-Protein (3-40)CAS: 161818-04-8
The pyroglutamate-modified amyloid-β peptides derived from Aβ40 (H-7422) and Aβ42 (H-4796) have gained considerable attention as potential key participants in the pathology of Alzheimer's disease (AD) due to their abundance in AD brain, high aggregation propensity, stability, and cellular toxicity. Aβ40 and 42 can be N-terminally truncated by action of cathepsin B. The cyclization of Glu³ is catalyzed by glutaminyl cyclase. Hence, inhibition of these enzymes could be a therapeutic approach to AD.
- (Pyr³)-Amyloid β-Protein (3-42)CAS: 183449-57-2
(Pyr³)-Amyloid β-Protein (3-42) was found to be the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. Therefore, (Pyr³)-Aβ (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits. Nussbaum et al. studies the Prion-like behaviour and tau-dependent cytotoxicity of the truncated Aβ sequence.
- (Thr²)-Amyloid β-Protein (1-42)
A mutation very close to the β-secretase cleavage site of APP. The Icelandic mutation A2T of Aβ42 turned out to be less pathogenic than the native sequence. The precursor APP A673T was the first APP variant discovered in humans reducing the risk of Alzheimer's disease. A2T as well affects γ-secretase cleavage, the mutant was an inefficient substrate in a cell-based assay of the enzyme.
- (Val²)-Amyloid β-Protein (1-42)
A mutation very close to the β-secretase cleavage site of APP (A673V). Contrary to the protective Icelandic mutation A2T, the recessive A2V mutation may increase the risk of Alzheimer's disease. Cantu et al. observed that APP A673V is associated with the early onset of AD-type dementia in homozygous individuals, whereas it has a protective effect in the heterozygous state.
- (Val³⁴)-Amyloid β-Protein (1-40)CAS: 1678415-83-2
Cerebral amyloid angiopathy (CAA) is a common finding in Alzheimer's disease in which amyloid-Aβ vascular deposits are featured in >80% of the cases. Mutations in the positions 21-23 (e.g. Dutch mutation E22Q) are primarily associated with CAA, although they manifest with strikingly different clinical phenotypes: cerebral hemorrhage or dementia. The Piedmont L34V Aβ mutant, located outside this hot spot, shows a similar hemorrhagic phenotype, albeit less aggressive than the widely studied Dutch variant.
- ent-Amyloid β-Protein (1-42)CAS: 342896-25-7
All-D Aβ (1-42) exhibits similar properites as the all-L Aβ. The peptide forms ion channels in lipid bilayers.
- Amyloid β-Protein (1-6) amideCAS: 1361235-89-3
Experiments using sub-peptides of Aβ42 revealed that the epitope identified by the antibody A8, as described by Ying and coworkers, lies within the 1-6 region of Aβ. The antibody displays high affinity for soluble Aβ42 oligomers in the molecular weight range of 16.5-25 kDa, and detected target antigen in brain sections from senescence-accelerated SAMP 8 mice. Amidated or acetylated and amidated forms of the sequence were used for example for quantitative structure retention relationships (QSRR) experiments. The latter could allow prediction of reversed-phase high-performance liquid chromatography (HPLC) retention of peptides, as reported by Kaliszan and coworkers.
- Amyloid β-Protein (25-35) amideCAS: 147490-49-1
Amyloid β-Protein (25-35) amide是β淀粉样蛋白(amyloid-β,Aβ)酰胺化的一种产物,其中β淀粉样蛋白的生成能力已被强烈降低。
- Biotinyl-Amyloid β-Protein (1-40)CAS: 183906-14-1
Biotinyl-Amyloid β-Protein (1-40) 是一种 N 端标记的生物素化淀粉样蛋白 ß-(1-40) 肽。
- Prion Protein (106-126) (human) (scrambled)CAS: 150469-23-1
The 21-peptide NGAKALMGGHGATKVMVGAAA, a scrambled sequence of the human prion protein (106-126), is an important control in the study of the biological activity of prion protein peptides.
Peptides - Activated Protein C (390-404), humanCAS: 146340-20-7
Activated Protein C (390-404), human 是一种维生素 K 依赖的丝氨酸蛋白酶活化蛋白 C (APC) 的多肽片段,可抑制 APC 的抗凝血活性。
Peptides - Kv3, Channel Containing Protein 567-585
Kv3, Channel Containing Protein (567-585) 是Kv3.1b 通道蛋白的567-586 氨基酸肽。Kv3 channel protein 在含有pallidal 神经元的 PV 蛋白表达。
Peptides - CEF14, EBV Rta Protein 28-37CAS: 216862-58-7
CEF14, EBV Rta Protein (28-37) 来自 Epstein-Barr 病毒 Rta 蛋白的 HLA A24 限制性表位。
Peptides - C-Reactive Protein (CRP) 201-206CAS: 130348-99-1
C-Reactive Protein (CRP) 201-206 是 C-反应蛋白的 201-206 片段。C-Reactive Protein 可作为炎症的标记,是心血管风险的标志物,可能促进动脉粥样硬化形成。
Peptides
| 货号 | 产品名称 | CAS号 | 靶点 / 通路 | 引用 | 结构 |
|---|---|---|---|---|---|
| GA20242 | (Lys¹⁵)-Amyloid β-Protein (15-21) | 190775-14-5 | Amyloid β protein | ||
KKLVFFA contains the KLVFF sequence, which is the minimum sequence binding the full-length amyloid β-protein. It showed improved water solubility compared with KLVFF (H-3682). It can be used as a labeled probe for screening defined sequences in the full-length amyloid β-protein. | |||||
| GA20244 | (Lys²²)-Amyloid β-Protein (1-40) | 302905-01-7 | Amyloid β protein | ||
The Italian mutation of β-amyloid 1-40 (E22K) aggregates more rapidly than the wild-type sequence 1-40. It showed increased neurotoxicity, which (according to a solid-phase NMR-study of Masuda et al.) may be due to the salt bridge formed between Lys²² and Asp²³ in the minor conformer. As the Arctic, Flemish, and Dutch mutants, the Italian mutant is degraded considerably more slowly than wild-type Aβ by neprilysin. | |||||
| GA20245 | (Lys²²)-Amyloid β-Protein (1-42) | 383200-59-7 | Amyloid β protein | ||
The Italian mutation (E22K) aggregates more rapidly than the wild-type sequence. | |||||
| GA20259 | (Nle³⁵)-Amyloid β-Protein (1-40) | 1802086-31-2 | Amyloid β protein | ||
The reactive thioether of Met³? is crucial for the activity of Aβ 1-40 and Aβ 1-42. Due to the replacement of Met by inert Nle, M35Nle Aβ 1-40 was no longer toxic to cultured hippocampal neurons and had little effect on the level of protein carbonyl residues. The Nle peptide showed the same propensity to aggregate, whereas sulfoxide formation hindered the required conformational transition from random coil to β-sheet. | |||||
| GA20260 | (Nle³⁵)-Amyloid β-Protein (1-42) | 1802086-51-6 | Amyloid β protein | ||
The thioether of Met³? plays a critical role in the oxidative stress induced by Aβ 1-42 and its neurotoxicity. The norleucine analog Aβ 1-42 M35Nle forms fibrils morphologically indistinguishable from the ones of the native sequence though lacking their neurotoxicity. | |||||
| GA20282 | (Pyr¹¹)-Amyloid β-Protein (11-40) | 192377-94-9 | Amyloid β protein | ||
pEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV, the N-terminally truncated isoform of the amyloid β-protein (Aβ) beginning with a pyroglutamate (Pyr) residue at position 11 was used in experiments studying the generality of fibrillogenesis-related helix formation. Comparing the fibrillogenesis kinetics of many of the most important clinically relevant amyloid β-protein alloforms it could be observed that among these peptides (Pyr¹¹)-amyloid β-protein (11-40) exhibited the greatest retardation of fibrillization rate. | |||||
| GA20283 | (Pyr³)-Amyloid β-Protein (3-40) | 161818-04-8 | Amyloid β protein | ||
The pyroglutamate-modified amyloid-β peptides derived from Aβ40 (H-7422) and Aβ42 (H-4796) have gained considerable attention as potential key participants in the pathology of Alzheimer's disease (AD) due to their abundance in AD brain, high aggregation propensity, stability, and cellular toxicity. Aβ40 and 42 can be N-terminally truncated by action of cathepsin B. The cyclization of Glu³ is catalyzed by glutaminyl cyclase. Hence, inhibition of these enzymes could be a therapeutic approach to AD. | |||||
| GA20284 | (Pyr³)-Amyloid β-Protein (3-42) | 183449-57-2 | Amyloid β protein | ||
(Pyr³)-Amyloid β-Protein (3-42) was found to be the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. Therefore, (Pyr³)-Aβ (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits. Nussbaum et al. studies the Prion-like behaviour and tau-dependent cytotoxicity of the truncated Aβ sequence. | |||||
| GA20309 | (Thr²)-Amyloid β-Protein (1-42) | - | Amyloid β protein | ||
A mutation very close to the β-secretase cleavage site of APP. The Icelandic mutation A2T of Aβ42 turned out to be less pathogenic than the native sequence. The precursor APP A673T was the first APP variant discovered in humans reducing the risk of Alzheimer's disease. A2T as well affects γ-secretase cleavage, the mutant was an inefficient substrate in a cell-based assay of the enzyme. | |||||
| GA20339 | (Val²)-Amyloid β-Protein (1-42) | - | Amyloid β protein | ||
A mutation very close to the β-secretase cleavage site of APP (A673V). Contrary to the protective Icelandic mutation A2T, the recessive A2V mutation may increase the risk of Alzheimer's disease. Cantu et al. observed that APP A673V is associated with the early onset of AD-type dementia in homozygous individuals, whereas it has a protective effect in the heterozygous state. | |||||
| GA20340 | (Val²)-Amyloid β-Protein (1-6) | 727727-66-4 | Amyloid β protein | ||
| GA20341 | (Val³⁴)-Amyloid β-Protein (1-40) | 1678415-83-2 | Amyloid β protein | ||
Cerebral amyloid angiopathy (CAA) is a common finding in Alzheimer's disease in which amyloid-Aβ vascular deposits are featured in >80% of the cases. Mutations in the positions 21-23 (e.g. Dutch mutation E22Q) are primarily associated with CAA, although they manifest with strikingly different clinical phenotypes: cerebral hemorrhage or dementia. The Piedmont L34V Aβ mutant, located outside this hot spot, shows a similar hemorrhagic phenotype, albeit less aggressive than the widely studied Dutch variant. | |||||
| GA21424 | ent-Amyloid β-Protein (1-42) | 342896-25-7 | Amyloid β protein | ||
All-D Aβ (1-42) exhibits similar properites as the all-L Aβ. The peptide forms ion channels in lipid bilayers. | |||||
| GA20728 | Amyloid β-Protein (1-40) (scrambled) | 1678415-68-3 | Amyloid β protein | ||
| GA20729 | Amyloid β-Protein (1-40) amide | 203460-31-5 | Amyloid β protein | ||
| GA20731 | Amyloid β-Protein (1-42) (scrambled) | 1678415-52-5 | Amyloid β protein | ||
| GA20739 | Amyloid β-Protein (1-6) amide | 1361235-89-3 | Amyloid β protein | ||
Experiments using sub-peptides of Aβ42 revealed that the epitope identified by the antibody A8, as described by Ying and coworkers, lies within the 1-6 region of Aβ. The antibody displays high affinity for soluble Aβ42 oligomers in the molecular weight range of 16.5-25 kDa, and detected target antigen in brain sections from senescence-accelerated SAMP 8 mice. Amidated or acetylated and amidated forms of the sequence were used for example for quantitative structure retention relationships (QSRR) experiments. The latter could allow prediction of reversed-phase high-performance liquid chromatography (HPLC) retention of peptides, as reported by Kaliszan and coworkers. | |||||
| GA20745 | Amyloid β-Protein (25-35) amide | 147490-49-1 | Amyloid β protein | ||
Amyloid β-Protein (25-35) amide是β淀粉样蛋白(amyloid-β,Aβ)酰胺化的一种产物,其中β淀粉样蛋白的生成能力已被强烈降低。 | |||||
| GA20823 | Biotinyl-Amyloid β-Protein (1-40) | 183906-14-1 | Amyloid β protein | ||
Biotinyl-Amyloid β-Protein (1-40) 是一种 N 端标记的生物素化淀粉样蛋白 ß-(1-40) 肽。 | |||||
| GA24156 | Prion Protein (106-126) (human) (scrambled) | 150469-23-1 | Peptides | ||
The 21-peptide NGAKALMGGHGATKVMVGAAA, a scrambled sequence of the human prion protein (106-126), is an important control in the study of the biological activity of prion protein peptides. | |||||
| GC35245 | Activated Protein C (390-404), human | 146340-20-7 | Peptides | ||
Activated Protein C (390-404), human 是一种维生素 K 依赖的丝氨酸蛋白酶活化蛋白 C (APC) 的多肽片段,可抑制 APC 的抗凝血活性。 | |||||
| GC36409 | Kv3, Channel Containing Protein 567-585 | - | Peptides | ||
Kv3, Channel Containing Protein (567-585) 是Kv3.1b 通道蛋白的567-586 氨基酸肽。Kv3 channel protein 在含有pallidal 神经元的 PV 蛋白表达。 | |||||
| GC35640 | CEF14, EBV Rta Protein 28-37 | 216862-58-7 | Peptides | ||
CEF14, EBV Rta Protein (28-37) 来自 Epstein-Barr 病毒 Rta 蛋白的 HLA A24 限制性表位。 | |||||
| GC35745 | C-Reactive Protein (CRP) 201-206 | 130348-99-1 | Peptides | ||
C-Reactive Protein (CRP) 201-206 是 C-反应蛋白的 201-206 片段。C-Reactive Protein 可作为炎症的标记,是心血管风险的标志物,可能促进动脉粥样硬化形成。 | |||||
